This acquisition integrates IMV's advanced DPX™ antigen delivery platform and cancer vaccine clinical development programs into BioVaxys' oncology vaccine technology portfolio, expanding the Company’s ovarian cancer pipeline and global research impact. Acquired from IMV Inc., the DPX™ platform is a cutting-edge lipid-based delivery system. It's designed for encapsulating a diverse array of bioactive molecules, leading to enhanced and sustained immune responses. Karl Landsteiner, is a process that uses chemicals called ‘haptens’ to train the immune system to recognize and aggressively target tumor or viral proteins, thus enhancing T cell response against both tumor and viral antigens. We collaborate with leading institutions and universities and hold exclusive patents in haptenized vaccine technologies and T cell-mediated immune response diagnostics.
This company is:
Verified
BioVaxys Broadens Intellectual Property Portfolio - Commercial Trademark Application Filed For CoviDTH® Diagnostic - Biovaxys
Cancer Vaccine Platform Patent Coverage Expanded To Now Include Over 12 Tumor Types Vancouver, British Columbia, April 29th, 2021 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:BVAXF) (“BioVaxys” or “the Company”), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced today that it has filed with the United States Patent & [...]
Verified
BioVaxys Further Expands Vaccines Intellectual Property Portfolio - Biovaxys
VANCOUVER, BC, September 28th, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today that in an action that further expands the value of their IP portfolio, the Company has broadened the patent coverage for its viral vaccine platform by filing an international patent application through the Patent Cooperation Treaty (“PCT”) [...]
Verified
BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone - Biovaxys
VANCOUVER, British Columbia, Sept. 17, 2021 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”), announced today that cancer vaccine manufacturing partner Bio Elpida in Lyon, France, has reached major milestones in the development of the bioproduction process for BVX-0918A, BioVaxys’ ovarian cancer vaccine and is beginning the next phase of manufacturing process development. [...]
View all products
Keywords
Industries
BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine - Biovaxys
Vancouver, British Columbia, October 20th, 2021 – BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has filed with the United States Patent & Trademark Office (“USPTO”) a provisional patent application for its haptenized viral antigen vaccine platform to elicit a broad cross-reactive immune response against most or all sarbecoviruses, [...]
Where is BioVaxys located?
The company BioVaxys is located in New York, New York, United States. It's worth noting that the company may has more corporate locations
How many employees does BioVaxys approximately have?
As of the latest available information BioVaxys has around 1-10 employees worldwide.
When was BioVaxys founded?
BioVaxys was founded in 2018
In which industries does BioVaxys mainly work?
The company BioVaxys has it's main focus in the industries of Biotechnology, Health Care, Science and Engineering
IMV
Canada
11-50 Employees
2000
Elicio Therapeutics
United States
11-50 Employees
2011
UbiVac
United States
1-10 Employees
2005
Morphogenesis
United States
11-50 Employees
1995
Immudex
Denmark
11-50 Employees
2009
Immunomic Therapeutics
United States
11-50 Employees
2005
ISA Pharmaceuticals
Netherlands
11-50 Employees
2004
Virovax Limited
United Kingdom
1-10 Employees
2016
Topics which have been searched by others and may be interesting for you:
